Quantcast

Latest Percutaneous coronary intervention Stories

2014-05-20 23:15:46

Accreditation for Cardiovascular Excellence (ACE) accredits academic medical center renowned as the birthplace of percutaneous coronary intervention (PCI). Washington, DC (PRWEB) May 20, 2014 The Accreditation for Cardiovascular Excellence (ACE) is proud to announce that Emory University Hospital and Emory University Hospital Midtown, Atlanta, GA, are the latest facilities recognized with provisional accreditation by ACE. Both academic hospitals successfully completed the ACE...

2014-05-15 16:28:10

-- Oral Presentations to Include New Long-Term Results from First-in-Human Study -- DURHAM, N.C., May 15, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced the updated three- and two-year clinical outcomes from its DESSOLVE I and II clinical trials, respectively, will be presented at the EuroPCR conference to be held in Paris, France from May 20 - 23. Two oral presentations will be made by William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium: -- DESSOLVE II...

2014-05-14 08:30:11

Conference Call and Webcast, May 14, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J., May 14, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results...

2014-05-09 08:25:47

BASKING RIDGE, N.J., May 9, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the Compensation Committee of Regado's Board of Directors granted an inducement award pursuant to NASDAQ Listing Rule 5635(c)(4) to R. Don Elsey in connection with his employment as Regado's Senior Vice President, Finance,...

2014-05-07 08:32:21

BASKING RIDGE, N.J., May 7, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Wednesday, May 14, 2014, at 8:30 a.m. EDT to discuss its first quarter 2014 financial results and corporate highlights. Interested participants and investors may...

2014-05-06 23:06:59

Blockages previously deemed untreatable now cleared through hybrid approach developed by interventional cardiologists. Kansas City, MO (PRWEB) May 06, 2014 Saint Luke’s Mid America Heart Institute interventional cardiologists are on the forefront of perfecting new minimally invasive approaches to treat chronic total occlusions (CTOs) – completely blocked arteries – which previously were deemed untreatable. One in five patients with plaque buildup has at least one completely...

2014-05-05 23:01:31

For 16 Consecutive Years Mount Sinai Awarded Highest “Two-Star” Rating by New York State Department of Health for Percutaneous Coronary Interventions (PCI) New York, NY (PRWEB) May 05, 2014 The Cardiac Catheterization Laboratory of Mount Sinai Heart at The Mount Sinai Hospital has once again received the highest “two-star” safety rating from the New York State Department of Health for its percutaneous coronary interventions (PCI) overall and in non-emergency cases. This marks the...

2014-04-15 08:31:02

SAN DIEGO, April 15, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results fiscal year ended December 31, 2013, and other recent developments. http://photos.prnewswire.com/prnvar/20140415/LA04094 Focus on Gene Therapy and Regenerative Medicine Biologics The Company recently announced that the U.S.-based Cardium Therapeutics operations will be primarily focused on the clinical and commercial development...

2014-04-10 08:30:25

- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market....

2014-04-02 20:22:41

REGULATE-PCI Opened to "All Comers" PCI Population BASKING RIDGE, N.J., April 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the...


Latest Percutaneous coronary intervention Reference Libraries

Coronary Angiography
2013-07-29 11:05:01

A coronary angiography, also known as a coronary catheterization, is a procedure that gives both visual and tactical access to coronary circulation and blood filled chambers of the heart for both diagnostic and interventional purposes. It is one of many diagnostic tests used in cardiology. More specifically, coronary catheterization recognizes occlusion, stenosis, thrombosis or aneurismal enlargement of the walls of the coronary arteries; heart chamber size; heart muscle contraction...

More Articles (1 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'